JP2025505575A5 - - Google Patents

Info

Publication number
JP2025505575A5
JP2025505575A5 JP2024545922A JP2024545922A JP2025505575A5 JP 2025505575 A5 JP2025505575 A5 JP 2025505575A5 JP 2024545922 A JP2024545922 A JP 2024545922A JP 2024545922 A JP2024545922 A JP 2024545922A JP 2025505575 A5 JP2025505575 A5 JP 2025505575A5
Authority
JP
Japan
Prior art keywords
patient
viral vector
administered
corticosteroid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505575A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061951 external-priority patent/WO2023150688A2/en
Publication of JP2025505575A publication Critical patent/JP2025505575A/ja
Publication of JP2025505575A5 publication Critical patent/JP2025505575A5/ja
Pending legal-status Critical Current

Links

JP2024545922A 2022-02-03 2023-02-03 ポンペ病の改善された治療のための組成物及び方法 Pending JP2025505575A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263306361P 2022-02-03 2022-02-03
US63/306,361 2022-02-03
US202263402850P 2022-08-31 2022-08-31
US63/402,850 2022-08-31
PCT/US2023/061951 WO2023150688A2 (en) 2022-02-03 2023-02-03 Compositions and methods for improved treatment of pompe disease

Publications (2)

Publication Number Publication Date
JP2025505575A JP2025505575A (ja) 2025-02-28
JP2025505575A5 true JP2025505575A5 (cg-RX-API-DMAC7.html) 2026-02-12

Family

ID=87552969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545922A Pending JP2025505575A (ja) 2022-02-03 2023-02-03 ポンペ病の改善された治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20250135038A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472658A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505575A (cg-RX-API-DMAC7.html)
KR (1) KR20240145491A (cg-RX-API-DMAC7.html)
AU (1) AU2023216268A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250992A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002307A1 (cg-RX-API-DMAC7.html)
IL (1) IL314586A (cg-RX-API-DMAC7.html)
MX (1) MX2024009519A (cg-RX-API-DMAC7.html)
TW (1) TW202342092A (cg-RX-API-DMAC7.html)
WO (1) WO2023150688A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658916B2 (en) * 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
AU2020372429A1 (en) * 2019-10-25 2022-04-28 Audentes Therapeutics, Inc. Compositions and methods for treating glycogen storage disorders
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
US20230149428A1 (en) * 2020-02-14 2023-05-18 Asklepios Biopharmaceutical, Inc. Method of treating gene therapy associated toxicity with antibiotics
WO2021202599A2 (en) * 2020-04-01 2021-10-07 Valiant Biosciences, Llc Adeno-associated virus based compositions and related methods for inducing humoral immunity

Similar Documents

Publication Publication Date Title
US7588757B2 (en) Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
GB2590880A (en) RNA and DNA base editing via engineered ADAR recruitment
CN102227500A (zh) 胆色素原脱氨酶基因治疗
Bellotti et al. Molecular approaches for the treatment of Pompe disease
AU2023202598B2 (en) Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
JP2022531809A (ja) ATPase媒介性疾患の処置のための組成物および方法
TW201629225A (zh) 第九因子基因療法
JP2022520232A (ja) ダノン病の治療のための遺伝子療法ベクター
JP2023524010A5 (cg-RX-API-DMAC7.html)
JP2022527597A (ja) 筋肉発現のためのハイブリッドプロモーター
US20240409955A1 (en) Auf1 combination therapies for treatment of muscle degenerative disease
JP2024545186A5 (cg-RX-API-DMAC7.html)
CA3257637A1 (en) AAV CAPSID MODIFIED BY A PEPTIDE EXHIBITING IMPROVED MUSCLE TRANSDUCTION EFFICIENCY
JP2022554141A5 (cg-RX-API-DMAC7.html)
JP2024520411A5 (cg-RX-API-DMAC7.html)
EP4090749A1 (en) Methods of treating phenylketonuria
RU2024125625A (ru) Композиции и способы для оптимизированного лечения болезни помпе
WO2024020574A2 (en) Auf1 gene therapy for limb girdle muscular dystrophy
US12630840B2 (en) One-step gene therapy for Duchenne muscular dystrophy via gene replacement and anti-inflammation
JP2024534415A5 (cg-RX-API-DMAC7.html)
RU2023134651A (ru) Композиции и способы улучшенного лечения х-сцепленной миотубулярной миопатии
US20250161483A1 (en) Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia
JP2024510972A5 (cg-RX-API-DMAC7.html)
CN120603602A (zh) 使用aav载体的斑菲素蛋白-2(pkp2)基因治疗
JP2026012759A (ja) 筋ジストロフィーを治療するための方法および組成物